Target intelligence / Profile preview

Actin alpha 2 (smooth muscle) (ACTA2)

Target
ACTA2
Molecular classification
Other, Cytoskeletal protein
01

Overview

Actin alpha 2 (ACTA2), also known as alpha-smooth muscle actin (α-SMA), is a highly conserved cytoskeletal protein that serves as a primary component of the contractile apparatus in smooth muscle cells. It plays a vital role in maintaining vascular tone and blood pressure homeostasis by interacting with myosin to generate mechanical tension within the arterial walls [2, 5, 10]. Beyond its structural function, ACTA2 is a critical biomarker for myofibroblast activation and epithelial-mesenchymal transition (EMT), making it a key indicator of tissue fibrosis and cancer progression in various organs [1, 3, 6]. Mutations in the ACTA2 gene are associated with life-threatening vascular conditions, including familial thoracic aortic aneurysms and dissections (TAAD), early-onset coronary artery disease, and multisystemic smooth muscle dysfunction syndrome (MSMDS) [5, 11, 16]. While current clinical management focuses on managing vascular symptoms using drugs like beta-blockers and ARBs, the protein is a significant target for anti-fibrotic drug development and experimental gene-editing therapies [14, 17]. Its essential role in global smooth muscle function presents a challenge for systemic targeting, often requiring localized or indirect modulation of its expression pathways [11, 19].

Other names
Alpha-smooth muscle actinα-SMAAlpha-actin-2Aortic smooth muscle actinACTSAAAT6MYMY5SMDYSGrowth-inhibiting gene 46
02

Mechanism of action

Modulation of vascular tone, inhibition of myofibroblast activation, regulation of TGF-beta signaling, and stabilization of actin filaments.

03

Biological functions

Muscle contractionCell motilityVascular contractilityBlood pressure homeostasisMaintenance of cell shapeMechanical tensionIntracellular signaling
04

Disease associations

Cardiovascular diseaseCancerInflammationThoracic aortic aneurysm and dissection (TAAD)Moyamoya diseaseMultisystemic smooth muscle dysfunction syndrome (MSMDS)FibrosisCoronary artery disease
05

Safety considerations

Systemic vascular dysfunctionHypotensionImpaired wound healingMultisystemic smooth muscle failureIncreased risk of perioperative stroke
06

Interacting drugs

Losartan

6 more in the full profile.

07

Biomarkers

Alpha-smooth muscle actin (myofibroblast marker)Cancer-associated fibroblast (CAF) markerMarker for epithelial-mesenchymal transition (EMT)Prognostic marker for lung adenocarcinomaMarker for liver fibrosis progression

Beyond the preview

Go deeper on Actin alpha 2 (smooth muscle) (ACTA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actin alpha 2 (smooth muscle) (ACTA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call